

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd. **上海百心安生物技術股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The supervisory committee (the “**Supervisory Committee**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Chenzhao ZHANG (張晨朝) (“**Mr. Zhang**”) resigned as an employee representative supervisor of the Company and other position in the Group with effect from August 31, 2023 as he would like to devote more time to other personal business.

Mr. Zhang has confirmed that he has no disagreement with the board of directors of the Company (the “**Board**”) and the Supervisory Committee and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board and the Supervisory Committee would like to express their sincere gratitude to Mr. Zhang for his contributions to the Company and the Supervisory Committee during his tenure of office as a supervisor of the Company.

As elected at the employees’ representatives meeting of the Company, Mr. Junyi WANG (王君毅) (“**Mr. Wang**”) was elected as an employee representative supervisor of the second session of the Supervisory Committee on August 31, 2023. The biographical details of Mr. Wang are set out as below:

Mr. Junyi Wang (王君毅), aged 34, has been the technical manager of the Group since July 27, 2016 and has served as the employee representative supervisor of the Company since August 31, 2023. Mr. Wang is primarily responsible for developing and promoting the research and development of the Group. He is also a limited partner of an employee incentive platform of the Group, Shanghai Baixinantong Enterprise Management Consulting L.P. (Limited Partnership)* (上海百心安通企業管理諮詢合夥企業(有限合夥)), holding 0.5% of its partnership interest. From June 2011 to January 2012, he worked as an experimental technician in Shanghai Construction Materials Co., Ltd.* (上海建工材料有限公司). From March 2012 to March 2013, he worked as a test engineer at Shanghai Lelai Automobile Analysis and Testing Co., Ltd.* (上海樂來汽車分析測試有限公司). From March 2013 to June 2016, he worked as a process engineer at Shanghai MicroPort Medical Devices (Group) Co., Ltd.* (上海微創醫療器械(集團)有限公司), a subsidiary of MicroPort Scientific Corporation (a company listed on the Stock Exchange with stock code: 0853), and was mainly responsible for the development of stents, guidewires and catheter products. Mr. Wang graduated from Shanghai University of Technology (上海應用技術大學) in June 2011. He is currently studying MBA at Glyndwr University in the United Kingdom.

Mr. Wang has confirmed that, save as disclosed above, as at the date of this announcement, he does not hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, and he does not hold any other major appointments and professional qualifications. He does not have any relationship with any director, supervisor, senior management, substantial shareholder or controlling shareholder (as defined under the Rules Governing the Listing of Securities on the Stock Exchange) of the Company, nor does he hold any position in the Company or any of its subsidiaries. Save as disclosed above, Mr. Wang does not have nor is deemed to have any interest in any shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) as at the date of this announcement.

Save as disclosed above, as at the date of this announcement, the Board is not aware of other information in respect of Mr. Wang as a supervisor of the Company that is required to be disclosed pursuant to the requirements set out in Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange, nor is there any matter that needs to be brought to the attention of the shareholders of the Company.

The term of office of Mr. Wang became effective from the conclusion of the employees' representatives meeting and will expire upon the election of employee representative supervisor of the third session of the Supervisory Committee. The Company will enter into a service contract with Mr. Wang, and Mr. Wang shall not receive any remuneration in his capacity as supervisor during his term of office but will only receive corresponding remuneration in his capacity and role in the Group.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive Director

Shanghai, the People's Republic of China, August 31, 2023

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. Wing Yiu DJEN as independent non-executive directors.

* *For identification purposes only*